Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ANAB OTCMKTS:IPHYF NASDAQ:OGI NASDAQ:PRQR On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeANABAnaptysBio$57.51+1.3%$60.26$11.40▼$72.36$1.67B0.72757,090 shs827,833 shsIPHYFInnate Pharma$1.65$1.67$1.37▼$2.25$138.32M0.27335 shsN/AOGIOrganigram Global$0.96-2.3%$1.24$0.95▼$2.24$135.80M1.43735,459 shs708,382 shsPRQRProQR Therapeutics$1.89+13.2%$1.62$1.33▼$3.10$199.13M0.07535,768 shs1.10 million shs7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleLooking for the next FAANG stock before everyone has heard about it? Click the link to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceANABAnaptysBio-1.46%+8.96%-3.35%-12.28%+138.33%IPHYFInnate Pharma0.00%0.00%-26.67%-23.43%-4.90%OGIOrganigram Global-2.26%-6.87%-6.43%-28.46%-27.94%PRQRProQR Therapeutics+9.87%+18.44%+10.60%+5.03%-11.64%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeANABAnaptysBio$57.51+1.3%$60.26$11.40▼$72.36$1.67B0.72757,090 shs827,833 shsIPHYFInnate Pharma$1.65$1.67$1.37▼$2.25$138.32M0.27335 shsN/AOGIOrganigram Global$0.96-2.3%$1.24$0.95▼$2.24$135.80M1.43735,459 shs708,382 shsPRQRProQR Therapeutics$1.89+13.2%$1.62$1.33▼$3.10$199.13M0.07535,768 shs1.10 million shs7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleLooking for the next FAANG stock before everyone has heard about it? Click the link to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceANABAnaptysBio-1.46%+8.96%-3.35%-12.28%+138.33%IPHYFInnate Pharma0.00%0.00%-26.67%-23.43%-4.90%OGIOrganigram Global-2.26%-6.87%-6.43%-28.46%-27.94%PRQRProQR Therapeutics+9.87%+18.44%+10.60%+5.03%-11.64%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceANABAnaptysBio 2.69Moderate Buy$81.8242.27% UpsideIPHYFInnate Pharma 0.00N/AN/AN/AOGIOrganigram Global 2.33HoldN/AN/APRQRProQR Therapeutics 2.63Moderate Buy$7.25289.78% UpsideCurrent Analyst Ratings BreakdownLatest ANAB, OGI, IPHYF, and PRQR Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/10/2026ANABAnaptysBio HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$95.006/9/2026OGIOrganigram Global Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D)6/8/2026PRQRProQR Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (E+) ➝ Sell (D-)6/2/2026ANABAnaptysBio Zacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold5/27/2026PRQRProQR Therapeutics CitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingMarket Outperform5/22/2026PRQRProQR Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D-) ➝ Sell (E+)5/15/2026ANABAnaptysBio Leerink PartnersSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price Target$90.005/13/2026ANABAnaptysBio Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D-) ➝ Sell (E+)5/13/2026ANABAnaptysBio UBS GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$60.00 ➝ $76.005/13/2026ANABAnaptysBio BarclaysSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOverweight$63.00 ➝ $75.005/4/2026ANABAnaptysBio Zacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold ➝ Strong-Buy(Data available from 6/18/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookANABAnaptysBio$234.60M7.13N/AN/A$1.34 per share42.92IPHYFInnate Pharma$10.19M13.57N/AN/A($0.29) per share-5.69OGIOrganigram Global$185.07M0.74N/AN/A$1.86 per share0.52PRQRProQR Therapeutics$17.99M10.89N/AN/A$0.53 per share3.51Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateANABAnaptysBio-$13.23M-$1.08N/A17.70N/A-11.53%-1,101.24%-7.75%8/5/2026 (Estimated)IPHYFInnate Pharma-$55.64MN/AN/AN/AN/AN/AN/AN/AN/AOGIOrganigram Global-$17.70M-$0.13N/A24.25N/A-9.22%-13.41%-9.09%8/12/2026 (Estimated)PRQRProQR Therapeutics-$47.73M-$0.50N/AN/AN/A-331.33%-84.87%-37.78%8/6/2026 (Estimated)Latest ANAB, OGI, IPHYF, and PRQR EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/12/2026Q1 2026ANABAnaptysBio-$0.6436-$1.84-$1.1965-$1.84$18.86 million$25.56 million5/12/2026Q2 2026OGIOrganigram Global-$0.01-$0.01N/A-$0.01$50.56 million$42.99 million5/12/2026Q1 2026PRQRProQR Therapeutics-$0.15-$0.15N/A-$0.15$5.19 million$2.35 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthANABAnaptysBioN/AN/AN/AN/AN/AIPHYFInnate PharmaN/AN/AN/AN/AN/AOGIOrganigram GlobalN/AN/AN/AN/AN/APRQRProQR TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioANABAnaptysBioN/A7.587.58IPHYFInnate PharmaN/A1.271.27OGIOrganigram GlobalN/A2.821.30PRQRProQR TherapeuticsN/A2.482.48Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipANABAnaptysBioN/AIPHYFInnate PharmaN/AOGIOrganigram Global34.63%PRQRProQR Therapeutics32.65%Insider OwnershipCompanyInsider OwnershipANABAnaptysBio33.50%IPHYFInnate Pharma31.89%OGIOrganigram Global0.09%PRQRProQR Therapeutics8.40%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableANABAnaptysBio10029.10 million19.35 millionOptionableIPHYFInnate Pharma17983.83 million57.10 millionNot OptionableOGIOrganigram Global1,139140.77 million140.64 millionOptionablePRQRProQR Therapeutics180105.36 million96.51 millionOptionableANAB, OGI, IPHYF, and PRQR HeadlinesRecent News About These CompaniesProQR Therapeutics N.V. (NASDAQ:PRQR) Given Average Recommendation of "Moderate Buy" by BrokeragesJune 15 at 2:15 AM | americanbankingnews.comPRQR Share News TodayJune 11, 2026 | uk.investing.comProQR Shareholders Approve Capital Increase, Board Changes at 2026 AGMJune 2, 2026 | tipranks.comProQR Posts Wider Q1 2026 Loss but Maintains Strong Cash PositionMay 17, 2026 | theglobeandmail.comProQR Therapeutics N.V. (NASDAQ:PRQR) Analysts Just Slashed This Year's Revenue Estimates By 22%May 14, 2026 | finance.yahoo.comProQR Announces First Quarter 2026 Operating and Financial ResultsMay 12, 2026 | globenewswire.comProQR Announces Multiple Upcoming Scientific Conference Presentations Highlighting the Breadth of its Axiomer™ RNA Editing PlatformMay 11, 2026 | globenewswire.comEarnings Preview: ProQR (PRQR) Q1 Earnings Expected to DeclineMay 7, 2026 | zacks.comProQR Announces Annual General Meeting of Shareholders to be Held June 2, 2026May 4, 2026 | globenewswire.comProQR Announces Nomination of Dr. Lykke Hinsch Gylvin to its Board of DirectorsApril 30, 2026 | globenewswire.comAnalysts’ Opinions Are Mixed on These Healthcare Stocks: Alkermes (ALKS), ProQR (PRQR) and Simulations Plus (SLP)April 10, 2026 | theglobeandmail.comProQR Therapeutics: Waiting On Proof As AX-0810 Data ApproachesApril 10, 2026 | seekingalpha.comProQR Highlights Pipeline Expansion and Multiple Upcoming Clinical Catalysts at Investor and Analyst EventApril 8, 2026 | globenewswire.comProQR Announces Partnership with Ginkgo Bioworks and Formation of AI Advisory BoardApril 8, 2026 | globenewswire.comGrowing optimism about ProQR Therapeutics (PRQR)’s RNA editing platform and future clinical catalystsMarch 26, 2026 | msn.comGrowing Optimism About ProQR Therapeutics (PRQR)’s RNA Editing Platform and Future Clinical CatalystsMarch 25, 2026 | insidermonkey.comProQR to Host Virtual Investor and Analyst Event Highlighting Pipeline on April 8, 2026March 25, 2026 | globenewswire.comProQR Therapeutics N.V. (PRQR) Presents at The Citizens Life Sciences Conference 2026 TranscriptMarch 18, 2026 | seekingalpha.comProQR (PRQR) Reports Q4 Loss, Lags Revenue EstimatesMarch 12, 2026 | zacks.comProQR Therapeutics N.V.: ProQR Announces Year End 2025 Operating and Financial ResultsMarch 12, 2026 | finanznachrichten.deNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All Headlines3 Space Infrastructure Stocks Gaining Momentum Ahead of the SpaceX IPOBy Ryan Hasson | May 20, 20265 Under-the-Radar AI Stocks to Watch in JuneBy Thomas Hughes | May 31, 2026AI Server Earnings: Wall Street Sees One Clear StandoutBy Leo Miller | June 5, 2026IREN Is Flipping the Switch from Bitcoin to AIBy Jeffrey Neal Johnson | May 28, 2026Palantir’s Drone Tailwind Puts Its Defense AI Story Back in Focus for InvestorsBy Chris Markoch | June 2, 2026ANAB, OGI, IPHYF, and PRQR Company DescriptionsAnaptysBio NASDAQ:ANAB$57.51 +0.74 (+1.30%) Closing price 04:00 PM EasternExtended Trading$57.54 +0.02 (+0.04%) As of 04:14 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.AnaptysBio, Inc., a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Rosnilimab, an IgG1 antibody that targets PD-1+ T cells, resulting in their agonism or depletion, broadly impacting pathogenic drivers of autoimmune and inflammatory diseases; and ANB032, a non-depleting antibody that binds to the BTLA checkpoint receptor and inhibits activated T cell proliferation; ANB033, a novel anti-CD122 antagonist antibody that targets the shared common beta subunit of the receptors for IL-15 and IL-2; ANB101, a BDCA2 modulator antibody that specifically targets plasmacytoid dendritic cells (pDCs); and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis. The company also focuses on developing various antibody programs that are advanced to preclinical and clinical milestones under its collaborations. It has a collaboration and license agreement with GlaxoSmithKline, Inc. The company was formerly known as Anaptys Biosciences, Inc. and changed its name to AnaptysBio, Inc. in July 2006. AnaptysBio, Inc. was incorporated in 2005 and is based in San Diego, California.Innate Pharma OTCMKTS:IPHYF$1.65 0.00 (0.00%) As of 06/17/2026Innate Pharma S.A., a biotechnology company, develops immunotherapies for cancer patients in France and internationally. The company's products include Lacutamab (IPH4102), an anti-KIR3DL2 antibody, which is in Phase II clinical trials for the treatment of cutaneous T-cell and peripheral T-cell lymphoma, as well as in Phase II clinical trials to treat refractory sézary syndrome; Monalizumab, an immune checkpoint inhibitor that is in Phase III clinical trial to treat advanced solid tumors comprising colorectal and lung cancer, as well as head and neck cancer; IPH5201, a blocking antibody that is in Phase II clinical trials targeting the CD39 immunosuppressive pathway; IPH5301, an anti-CD73 antibody targeting the immunosuppressive adenosine pathway to promote antitumor immunity; IPH6401, an BCMA-targeting NK cell engager; and IPH6101, a NKp46-based NK cell engager that targets CD123 proprietary multi-specific antibody format; and IPH62, an B7-H3-targeting NK cell engager. Its products in preclinical trials are IPH43, an anti-MICA/B ADC and IPH45, an antibody drug conjugates (ADC); and IPH67, an undisclosed, multi-specific ANKET. The company has licensing and collaboration agreements with AstraZeneca, Novo Nordisk A/S, Sanofi, and Orega Biotech; and co-development and license agreement with MedImmune Limited. Innate Pharma S.A. was incorporated in 1999 and is headquartered in Marseille, France.Organigram Global NASDAQ:OGI$0.96 -0.02 (-2.28%) Closing price 04:00 PM EasternExtended Trading$0.96 +0.00 (+0.03%) As of 06:51 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Organigram Holdings Inc., through its subsidiaries, engages in the production and sale of cannabis and cannabis-derived products in Canada. It offers medical cannabis products, including whole flower, milled flower, pre-rolls, infused pre-rolls, vapes, gummies, and concentrates for medical retailers; adult use recreational cannabis under the SHRED, Holy Mountain, Big Bag O' Buds, Monjour, Trailblazer, SHRED'ems, Edison Cannabis Co., Edison JOLTS, Tremblant, and Laurentian brands. The company also engages in the wholesale shipping of cannabis plant cuttings, dried flowers, blends, pre-rolls, and cannabis derivative-based products to retailers and wholesalers for adult-use recreational cannabis. It sells its products through online, as well as consumer channels. The company was incorporated in 2010 and is headquartered in Toronto, Canada.ProQR Therapeutics NASDAQ:PRQR$1.89 +0.22 (+13.17%) Closing price 04:00 PM EasternExtended Trading$1.84 -0.05 (-2.91%) As of 06:35 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.ProQR Therapeutics N.V., a biotechnology company, focuses on the discovery and development of novel therapeutic medicines. The company's products pipeline includes AX-0810 for cholestatic diseases targeting Na-taurocholate cotransporting polypeptide (NTCP); and AX-1412 for cardiovascular diseases (CVDs) targeting Beta-1,4-galactosyltransferase 1 (B4GALT1). It also develops various other early-stage research programs, including AX-1005 for undisclosed targets in CVDs; AX-2402, which focuses on Rett syndrome; AX-2911 for nonalcoholic steatohepatitis (NASH); AX-0601 for obesity and Type 2 diabetes; and AX-9115 for rare metabolic condition, as well as various other targets. In addition, the company develops Axiomer RNA base-editing platform technology. It has a license agreement with Radboud University Medical Center; Inserm Transfert SA; Ionis Pharmaceuticals, Inc.; Vico Therapeutics B.V.; University of Rochester; and Leiden University Medical Center, as well as license and research collaboration with Eli Lilly and Company for the discovery, development, and commercialization of potential new medicines for genetic disorders in the liver and nervous system. The company was incorporated in 2012 and is headquartered in Leiden, the Netherlands. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Credo Technologies Accelerates AI—Its Stock Price Will Follow Why Rocket Lab’s Nasdaq-100 Moment Could Change the Story Qualcomm Goes All-In: The $10B Bet to Crush NVIDIA CarMax In Reverse? Why You Should Buy Now Before the Big Catalysts Emerge Jabil Just Gave Investors a Stronger Reason to Buy the Dip USA Rare Earth Just Moved Closer to Commercial Reality After an Initial Panic, Wall Street's Leaning Into Apple's New Siri AI CoreWeave Insider Sales Look Big, But Should Investors Worry? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
